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Abstract
Metachromatic Leukodystrophy is a rare disorder with great clinical variability. We report the first 
case of triplets with the late infantile form of the disease and their systematic progression of 
symptoms. We reviewed the literature and identified all human studies that reported new cases 
since 1921. We analyzed survival by decade to assess the impact of historical changes in 
management of care. Mean age at death and 5-year survival from onset of symptoms for late 
infantile, juvenile and adult phenotype were 4.2 years and 24.9%, 17.4 years and 70.3%, and 43.1 
years and 88.6% respectively. 5-year survival of cases reported after 1990 was significantly better 
than cases reported before 1970 in all subtypes of metachromatic leukodystrophy (late infantile: 
52% vs. 14%, juvenile: 100% vs. 46%, adult: 95% vs. 67%). Survival in the late infantile subtype 




Metachromatic Leukodystrophy is an autosomal recessive inherited disease with a 
deficiency of the lysosomal enzyme arylsulfatase A1. This results in accumulation of 
sulfated glycolipids in the myelin sheaths of the nervous system and to a lesser extent in 
visceral organs like liver, gallbladder and kidney1. In the central nervous system this 
accumulation results in progressive demyelination. metachromatic leukodystrophy is 
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subdivided into three clinical subtypes according to age of onset: late-infantile, juvenile and 
adult 1,2. The impact of genetic and environmental factors is not well understood.
Clinical, radiological and laboratory findings in these subtypes have previously been 
reported, however the composite overall survival of these patients remains unknown. To 
explore this further we reviewed the literature since description of the first metachromatic 
leukodystrophy patient in 19213. We describe triplets with late infantile onset 
metachromatic leukodystrophy, two identical and one fraternal, who share a common 
environment, have the same genetic mutations and demonstrate a remarkable synchronicity 
in neurological decline.
Case Report
The triplets were born via cesarean section at 29 weeks gestation. Two boys were identical 
twins and one was fraternal. The mother had suffered from fetal alcohol syndrome and had a 
history of developmental delay and depression. Aside from bed rest, the pregnancy was 
unremarkable. Their Apgar scores were 8 and 8 at 1 and 5 minutes respectively. They had a 
typical neonatal intensive care unit course, which included evaluation for sepsis and possible 
necrotizing enterocolitis, apnea and bradycardia. Cranial ultrasounds revealed no intracranial 
hemorrhage. The triplets were in the neonatal intensive care unit for approximately two 
months and then discharged home on routine oral feedings without a requirement for 
supplemental oxygen or medications.
Initially, developmental progress was achieved in all domains. The triplets rolled over at 10 
months, sat up at 11 months, began crawling at 12 months and walking at 15 months. By 16 
months they were speaking in 2 to 3 word sentences, feeding themselves with utensils and 
adequately navigating through fine motor tasks.
Around 16 months of age, there was a rapid and striking change in development in the three 
boys. Regression in motor skills was recognized first. The gross motor skills were more 
affected than the fine motor skills. They lost their ability to walk, crawl, sit up, and roll over. 
Loss of head control followed. During that time, the family noted left-sided ptosis in all 
three. Over the next few weeks their speech and language skills declined to the expression of 
one-syllable words. They also lost fine motor skills and pincer grasp. Deep tendon reflexes 
were preserved.
A battery of metabolic and genetic testing was performed, including plasma amino acids, 
urine organic acids, cerebrospinal fluid neurotransmitters and amino acids. All were within 
normal range. A brain MRI showed T2 hyperintense periventricular lesions that were 
difficult to distinguish from normal terminal myelination zones (Figure 1A). Measurement 
of arylsulfatase A activity in leukocytes showed levels of 4.5, 7.8 and 8.1 nmol/h/mg protein 
in the triplets versus a normal mean of about 80 nmol/h/mg protein. Urine analysis showed 
an increase in sulfatides, confirming the diagnosis of metachromatic leukodystrophy. DNA 
analysis revealed one copy of the common LI mutation (G459+1A) in each child. The other 
mutation in these children is a deletion starting between intron 6 and exon 8 and extending 
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beyond the end of the gene. These are both severe mutations likely to lead to a late infantile 
presentation.
By 24 months of age, they developed progressive truncal hypotonia with peripheral 
spasticity. All three displayed persistent fisting of the hands, facial weakness, and diffuse 
hyperreflexia. A nerve conduction study revealed normal conduction velocities in the 
median, ulnar, tibial and peroneal nerves.
At 36 months of age they began to complain of pain with minimal passive movement of the 
limbs, particularly the legs. This was aggravated during activities such as dressing and 
physical activity but did not occur at rest or when unprovoked. Pain episodes led to 
increased dystonia and worsened spasticity. Progressive lower extremity spasticity, 
especially in the gastrocnemius, led to plantar flexion of the feet at rest. Baclofen was 
initiated to alleviate the worsening spasticity. Hip radiographs did not reveal uncovering of 
subluxation of the femoral heads. Regarding development, they continued to use single 
words, identify body parts through pointing, smile and have meaningful interactions with 
their parents and caregivers.
In the subsequent months they developed oromotor dysfunction and difficulty with weight 
gain. A swallow study documented aspiration of thin liquids. All three children underwent 
surgery for gastric tube placement. For the next several months, no aspiration problems or 
airway obstruction occurred. None of the triplets had seizures, either clinically or 
electrographically. Gastric motility slowed and continuous feeds with frequent breaks and 
venting were required to maintain comfort. Gabapentin was initiated to help with 
neuropathic-enteral pain. Over time, the boys’ nutritional status declined secondary to the 
feeding intolerance. They developed iron deficiency. A follow-up MRI was performed at 4 
years of age and confirmed radiographic progression of white matter disease in all three (see 
Figure 1B). The boys became less interactive and required increased levels of voice and 
tactile stimulation to respond.
Literature Review Methods
We undertook a systematic review to identify human studies of metachromatic 
leukodystrophy that reported new cases. We searched PubMed from 1920 through June 30th, 
2006 using the terms: “Metachromatic”, “Leukodystrophy”, “MLD” (metachromatic 
leukodystrophy), and combinations of these terms. Additionally, we manually reviewed the 
reference lists of all the other publications for other potential data sources. This search was 
repeated four times by two reviewers (AM and HWM) independently. Data abstraction was 
done by one reviewer (AM or HWM or FE) and verified independently by one of the other 
two reviewers. We only included studies that reported new cases with definite diagnosis of 
metachromatic leukodystrophy. We used the subtypes as assigned by the original 
publication. In the absence of definitive subtype, we assigned the subtype considering 
manifestations, its rate of progression and age at the onset of symptoms (late infantile: 0.5–4 
years, juvenile 4 – 16 years, adult > 16 years). Studies were excluded if they did not provide 
either: a) age at the onset of symptoms, or b) age at death or last follow-up. We also 
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excluded studies limited exclusively to patients receiving transplants. Sufficient information 
on ethnicity of the patients was not available and thus it was not included in the analysis.
Survival analyses, as function of years since onset of symptoms, were performed using the 
Kaplan-Meier and Cox proportional hazard method and log-rank test using the statistical 
software package STATA 8 (College station, Texas). When the date of death was not 
known, the record was censored in the analysis as of the date of last follow-up. To assess the 
impact of historical changes in management of care we analyzed survival by decade in the 
three phenotypes.
Results
We identified 142 eligible studies and information about 303 cases was extracted. The first 
included case occurred in 1921,reported by Witte et al3. Ninety-eight patients of the late 
infantile subtype from 50 studies4–53, 78 patients of the juvenile subtype from 42 studies22, 
24, 26, 27, 30, 49, 50, 54–88, and 127 patients of the adult onset subtype from 69 studies3, 
7, 14, 22, 27, 30, 81–144 were identified and are summarized in Table 1.
Symptoms in the late infantile group were poorly reported in general but well illustrated in 
our case report. Out of 38 late infantile cases for which detailed clinical features were 
provided, 61% patients presented with motor or gait abnormalities and 39% patients 
presented with seizures. In the juvenile group, 66% presented with inattention and 
difficulties at school, 26% with gait difficulties, 18% with tremor or ataxia, 13% with 
neuropathy and 5% with seizures. In the adult group, 72% presented with dementia and 
behavioral difficulties, 16% with psychosis and schizophrenia, 28% with neuropathy, and 
12% with seizures.
Survival
In all three subtypes, both sexes were equally affected, and there was no gender difference in 
survival (late infantile p=0.115, juvenile p=0.955, adult p=0.688). In the late infantile 
subgroup, 62/98 (63.3%) of patients were reported to have died at a mean age of 4.2 years. 
In the juvenile subgroup, 30/75 (38.5%) patients died at a mean age of 17.4 years. In the 
adult subtype, 35/127 (28%) died at a mean age of 43.1 years. 5-year and 10-year survival in 
these types are depicted in table 1 and figure 2.
When comparing survival in patients whose manifestation started before two years of age 
(n=79) with patients who manifested at and after two years (n=19), we did not find any 
significant difference (p=0.765). Similarly in the juvenile subtype, a cut-off of six years of 
age at initial manifestation did not affect the survival [4–6 group (n=13) versus 6–16 group 
(n=61), p=0.365]. However, the 19 patients whose age at onset of disease was between two 
and four years (classified as late infantile) performed significantly worse than those 13 
patients whose disease started between four and six years (classified as juvenile) (p<0.001). 
Overall survival was better in patients with the adult subtype than the late infantile or 
juvenile subtype (p<0.001 and p=0.005 respectively).
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The analysis by decades (1921–2006) showed that survival significantly improved over time 
in all subtypes as depicted in figure 3. 5-year survival of cases reported after 1990 was 
significantly better than the cases reported before 1970 in all subtypes of metachromatic 
leukodystrophy.
Discussion
In this study we described the first case of triplets with the late infantile form of the disease 
and their systematic and synchronous progression of symptoms. We performed a pooled 
survival analysis of 303 metachromatic leukodystrophy cases published as single case 
reports and small series over a nearly 80-year period in order to shed more light on the 
natural history of metachromatic leukodystrophy than was previously available. Survival in 
the late infantile subtype was worse than the other two subtypes. Adult patients had the most 
favorable disease course, with a median survival from the time of diagnosis of 25 years. 
Interestingly, we found an increase in survival in all age groups over time, and in absence of 
disease modifying or curative therapies this likely reflects improvement in supportive care 
alone. Survival was similar in patients within the same subtype and did not change with age 
at symptom onset within subtype.
As our case report of triplets with progressive spastic body paresis demonstrates, disease 
progression in the late infantile form of metachromatic leukodystrophy is remarkably 
systematic. As in 61% of reported cases, the triplets’ first symptom was motor regression. 
They lost their ability to walk within a few days of each other due to rapid progression in 
lower extremity muscle tone. Left-sided ptosis was noted in all three at 32 months of age. 
Significant gastric dysmotility led to major feeding discomfort and malnutrition. The late 
infantile form of this disease is a devastating diagnosis of limited life expectancy.
Our review of historical data found that only 50% of infants with metachromatic 
leukodystrophy survive beyond 2.7 years after their 1st symptoms. The 5-year survival was 
25%. Of note, however, milder cases may have been under-reported. Caution must be 
exercised in extrapolating the rate of progression from the age of death. In our experience, a 
rapid clinical decline does not necessitate short survival. With measures of gastric tube 
placement, hygiene precautions and adequate antibiotic coverage, patients can survive in a 
vegetative state for months and years. We note that 5-year survival has improved since 
1970. Despite the fact that no changes in treatment occurred, survival improved, probably 
due to improved supportive care.
The initial symptoms in the juvenile and adult metachromatic leukodystrophy patients are 
predominated by behavioral difficulties. The insidious nature of cognitive symptoms poses 
problems in early recognition and challenge clinicians across disciplines. Some 
metachromatic leukodystrophy patients with juvenile disease can benefit from hematopoietic 
stem cell transplantation if performed early in the course 66, 145. Recently, adult patients 
with metachromatic leukodystrophy have also been transplanted. Better techniques for early 
diagnose are urgently needed.
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While the present therapeutic options for metachromatic leukodystrophy are very limited, 
recent progress in the technology of enzyme replacement and gene therapy has been 
made146. Animal models of metachromatic leukodystrophy have been partially cured by 
both interventions146, 147. It remains to be seen whether enzyme replacement therapy will 
have long-term benefit for the central nervous system; one may envisage that it could be 
used in combination with other approaches. The impact of novel therapies will have to be 
measured against the defined clinical variability presented in our study. The survival 
patterns we derive from a review of the literature cannot replace a carefully conducted 
natural history study in order to establish the rate of progression of metachromatic 
leukodystrophy.
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Brain MRI of triplets at 15 months (A) and 4 years (B) of age. Axial fast fluid-attenuated 
inversion recovery (repetition time = 10,000 milliseconds, echo time = 140 milliseconds, 
inversion time: 2200 milliseconds) images are shown.
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Comparison of survival probability from onset of symptoms in the three subtypes of 
metachromatic leukodystrophy.
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Comparison of 5-year survival probability in three subtypes over time.
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